Roche

News

Mark Dawson named head of Roche's pRED unit

Roche has appointed leading Australian cancer researcher Mark Dawson to lead its pRED R&D division, as the company prepares for a steep patent cliff.

News

Roche trial offers hope to patients with rare kidney disease

A study of Roche's Gazyva has raised the prospect of a first approved therapy for the rare kidney disorder primary membranous nephropathy.

News

Data builds on Roche's dominance in primary progressive MS

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

CMS's Medicare price negotiations start round three

The US federal government has named the next 15 big-selling medicines that will be subject to Medicare pricing negotiations.

News

Roche claims midstage win for obesity injectable

Roche reports weight loss of up to 22.5% with its injectable GIP/GLP-1 agonist obesity drug, setting up phase 3, but will it be too late to the table?

News

NICE backs Roche lupus drug that supports kidney function

Roche's Gazyvaro, a drug that can restore kidney function in lupus nephritis, has been cleared for use by the NHS in England and Wales.

Mark Dawson named head of Roche's pRED unit

Roche trial offers hope to patients with rare kidney disease

Data builds on Roche's dominance in primary progressive MS

CMS's Medicare price negotiations start round three

Roche claims midstage win for obesity injectable

NICE backs Roche lupus drug that supports kidney function

NHS "isn't delivering equitable care for rare diseases"

Using AI-driven synthetic personas to take your insights fur...

Roche

Editor's Picks